⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SGMO News
Sangamo Therapeutics, Inc. Common Stock
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
globenewswire.com
SGMO
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
globenewswire.com
SGMO
Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
globenewswire.com
NVS
GILD
BMY
REGN
CRSP
NTLA
EDIT
BBIO
AZN
SGMO
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
globenewswire.com
SGMO
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
globenewswire.com
SGMO
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
globenewswire.com
SGMO
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight
prnewswire.com
NVO
ULTX
SGMO
PFE
BMN
SNY
CHGC
RHHBY
ALNY
BIIB
BAY
TSEM
CSL
HEMA
LFB
OCT
SOBI
ASC
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
globenewswire.com
SGMO
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
globenewswire.com
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
globenewswire.com
SGMO